UNASSIGNED: 89 Background: Oncoplastic surgery fuses @entity0 surgical and reconstructive techniques, both simple and complex. Following sculpting and removing the appropriate @entity5 , tissue rearrangement is utilized to minimize the dead space. PBI with brachytherapy provides excellent @entity5 control in this population. This study investigates cosmetic outcome and @entity137 in select stage 0, 1, and 2 @entity0 treated by a single breast surgeon and radiation oncologist. METHODS: 140 @entity1 were treated between May 2010 and December 2013 with breast conservation, @entity1817 ( @entity1817 ), and interstitial brachytherapy. Selection criteria included @entity1 of any age, any subtype, @entity5 size less than < 3 cm, N0 or N1mic, with excision margins > 1 mm. Strict modified Harvard cosmesis scale was used by direct examination by the surgeon, not photos. @entity137 was judged by the surgeon at the time of each follow-up, using the CTCAE scale, version 4. Median follow-up is 2 years. RESULTS: Two @entity1 were lost to follow-up. There were no in-breast and 1 axillary recurrence. Grade 2 or higher @entity137 were seen in 10 @entity1 (7.2%, one of whom had Lupus), and only 1 lasted beyond a year. @entity137 included 1 transient @entity0 , 1 late @entity1271 at one year, 1 grade 4 (0.7%), 0 grade 3, 5 grade 2 (3.6%), and 7 grade 1 fat @entity39 , 3 grade 2 @entity82 (2.2%), and only 1 transient arm @entity4269 (all @entity1 had @entity1817 ). Cosmesis was judged as poor in 1 (0.7%), fair in 2 (1.4%), good in 19 (14%), and excellent in 116 (84%). Pockmarks were visible on casual examination in 8% after one year. CONCLUSIONS: Oncoplastic surgery combined with sentinel node mapping and interstitial brachytherapy has resulted in low @entity137 (7.2%) and high rates of acceptable cosmesis (98% good/excellent), as scored by a single surgeon with strict criteria at each follow-up visit. No conclusions about @entity5 control will be made until this cohort has mature follow-up.

XXXX and cosmesis after oncoplastic surgery and interstitial brachytherapy.

@entity1 :: ('9606', 'Species') :: ['women', 'patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'Toxicity', 'toxicities'] @entity82 :: ('MESH:D005355', 'Disease') :: ['fibrosis'] @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancers', 'breast cancer', 'breast edema'] @entity39 :: ('MESH:D009336', 'Disease') :: ['necrosis'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'malignancy'] @entity4269 :: ('MESH:D008209', 'Disease') :: ['lymphedema'] @entity1817 :: ('MESH:D012804', 'Disease') :: ['sentinel node biopsy', 'SNB'] @entity1271 :: ('MESH:D008413', 'Disease') :: ['mastitis']
@entity137 :: (MESH:D064420,Disease) :: ['Toxicity']
